Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Looking for short term gigs? Discover where to find quick cash options that fit your schedule.
25,797 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Barclays lifts Atlassian price target to $112, signaling growing confidence in the company’s ARR trajectory and enter...
A clear, practical look at Expedia's Q1 2026 earnings, what drove results, and what to watch next. Learn the segments...
When Palantir reveals new AI-focused capabilities, Nvidia stock often faces a unique set of pressures. This guide bre...
Investors are watching PLBY closely as plby (plby) 2026 earnings unfold. This article breaks down Q1 results, evaluat...
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
The kiplinger letter spots trap emerges as a focal point in retirement planning as 401(K) plans weigh adding private ...
A new 2026 survey shows Gen Z is leaning into financial independence, saying ‘no’ more often to costly experiences an...
FuelCell Energy leads a hydrogen stock rebound with a 15% jump as investors chase AI data center exposure. Bloom Ener...
Investors noticed a notable move in Ross Stores shares as the off-price retailer reported stronger results and a heal...
Glamsterdam targets a mid-2026 mainnet upgrade that aims to ease congestion and boost Ethereum’s throughput. Analysts...
Klarna and Sezzle stand out in the evolving fintech scene, but they offer very different risk/reward profiles. This g...